- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rigel Pharmaceuticals Inc (RIGL)
Rigel Pharmaceuticals Inc stock price live, this page displays NASDAQ RIGL stock exchange data. View the RIGL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Rigel Pharmaceuticals Inc real time stock price chart below.
What Is the Rigel Pharmaceuticals Inc Stock Price Today?
The Rigel Pharmaceuticals Inc stock price today is 27.040.
What Is the Stock Symbol for Rigel Pharmaceuticals Inc?
The stock symbol for Rigel Pharmaceuticals Inc is "RIGL."
What Stock Exchange Does Rigel Pharmaceuticals Inc Trade On?
Rigel Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Rigel Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Rigel Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RIGL quote. (ISIN: US7665597024)
What Is the Rigel Pharmaceuticals Inc Stock Price Today?
The Rigel Pharmaceuticals Inc stock price today is 27.040.
What Is the Stock Symbol for Rigel Pharmaceuticals Inc?
The stock symbol for Rigel Pharmaceuticals Inc is "RIGL."
What Stock Exchange Does Rigel Pharmaceuticals Inc Trade On?
Rigel Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Rigel Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Rigel Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RIGL quote. (ISIN: US7665597024)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
26.270
27.165
52 wk Range
15.500
52.240
RIGL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
26.27027.165
52 wk Range
15.50052.240
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RIGL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
51.200
Upside
+89.35%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- Form 13G Rigel Pharmaceuticals Inc For: 27 March
- Investing.com
- Form 8K Rigel Pharmaceuticals Inc For: 3 March
- Investing.com
- Form 13G Rigel Pharmaceuticals Inc For: 27 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Rigel Pharmaceuticals Inc SWOT Analysis
Pipeline Promise | Explore Rigel's R289 and fostamatinib candidates, showing potential in MDS and sickle cell disease, driving future growth prospects |
Financial Turnaround | Rigel achieves positive net income, showcasing strong revenue growth and effective expense management in hematology and oncology sectors |
Market Positioning | Delve into Rigel's strategy of leveraging commercial success to fund pipeline development, balancing current products with future innovations |
Analyst Outlook | Price targets range from $15 to $57, reflecting diverse views on Rigel's growth potential in the competitive biotech landscape |
Rigel Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Rigel reported Q4 2025 net product sales of $65.4M, up 41% YoY, driven by TAVALISSE's 47% growth as primary revenue driver.
- Full-year 2025 net income surged to $367M from $17.5M in 2024; cash position doubled to $155M from $77.3M year-over-year.
- FY2026 guidance projects quarterly EPS of $0.85-$1.40 and full-year revenue of $281.05M, reflecting continued portfolio expansion.
- Stock declined 0.06% to $34.6 in aftermarket trading despite strong results, with shares trading near 52-week low amid investor caution.
- CEO highlighted successful transformation from single to multi-product firm; CFO noted tax strategy benefits reflecting confidence in profitability.
Last Updated: 2026-03-03, 05:38 p/m
Read Full TranscriptCompare RIGL to Peers and Sector
Metrics to compare | RIGL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRIGLPeersSector | |
|---|---|---|---|---|
P/E Ratio | 1.4x | 19.2x | −0.4x | |
PEG Ratio | 0.00 | 0.02 | 0.00 | |
Price/Book | 1.3x | 4.4x | 2.6x | |
Price / LTM Sales | 1.7x | 5.1x | 3.1x | |
Upside (Analyst Target) | 86.8% | 269.8% | 56.1% | |
Fair Value Upside | Unlock | 13.1% | 8.1% | Unlock |
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 51.200
(+89.35% Upside)
Earnings
Latest Release
Mar 03, 2026
EPS / Forecast
13.55 / 0.03
Revenue / Forecast
69.8M / --
People Also Watch
FAQ
What Is the Rigel (RIGL) Stock Price Today?
The Rigel stock price today is 27.040 USD.
What Stock Exchange Does Rigel Trade On?
Rigel is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Rigel?
The stock symbol for Rigel is "RIGL."
What Is the Rigel Market Cap?
As of today, Rigel market cap is 499.140M USD.
What Is Rigel's Earnings Per Share (TTM)?
The Rigel EPS (TTM) is 19.480.
From a Technical Analysis Perspective, Is RIGL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Rigel Stock Split?
Rigel has split 2 times.
How Many Employees Does Rigel Have?
Rigel has 173 employees.
What is the current trading status of Rigel (RIGL)?
As of Apr 01, 2026, Rigel (RIGL) is trading at a price of 27.040 USD, with a previous close of 25.720 USD. The stock has fluctuated within a day range of 26.270 USD to 27.165 USD, while its 52-week range spans from 15.500 USD to 52.240 USD.
What Is Rigel (RIGL) Price Target According to Analysts?
The average 12-month price target for Rigel is 51.200 USD, with a high estimate of 71 USD and a low estimate of 38 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +89.35% Upside potential.
What Is the RIGL Premarket Price?
RIGL's last pre-market stock price is 25.930 USD. The pre-market share volume is 30.000, and the stock has decreased by 0.210, or 0.820%.
What Is the RIGL After Hours Price?
RIGL's last after hours stock price is 27.210 USD, the stock has decreased by 0.170, or 0.630%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.